Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus

EuroIntervention 2014;10:74-82 published online ahead of print December 2013. DOI: 10.4244/EIJV10I1A13

Si-Hyuck Kang1, MD; Keun Ho Park, MD2; Hyo-Suk Ahn1, MD; Kyung Woo Park1, MD; Young Joon Hong2, MD; Bon-Kwon Koo1, MD; Myung Ho Jeong2, MD; Hyo-Soo Kim*1, MD

1. Cardiovascular Centre, Seoul National University Hospital, Seoul, South Korea; 2. Heart Research Centre of Chonnam National University Hospital, Gwangju, South Korea

Aims: Patients with diabetes mellitus have a higher risk of adverse events after percutaneous coronary intervention (PCI). This study aimed to elucidate the relative efficacy of everolimu

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

diabetes mellitusdrug-eluting stentspercutaneous coronary intervention

Share on Facebook Share on Twitter Share on Linkedin

Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus

Read next article

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke